Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

Emerging biopharmaceuticals from marine actinobacteria

(2017) Syed Shams ul Hassan et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

(2017) Khaldoun Almhanna et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

(2017) Antonio Jimeno et al.   INVESTIGATIONAL NEW DRUGS

Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer

(2017) L. van Andel et al.   INVESTIGATIONAL NEW DRUGS

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

(2017) L. van Andel et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs

(2017) Verónica Ruiz-Torres et al.   MOLECULES

Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial)

(2016) Russell Petty et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cancer control potential of marine natural product scaffolds through inhibition of tumor cell migration and invasion

(2016) Mudit Mudit et al.   DRUG DISCOVERY TODAY

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

(2016) C. M. Nijenhuis et al.   DRUG METABOLISM REVIEWS

Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

(2016) Luis Paz-Ares et al.   INVESTIGATIONAL NEW DRUGS

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma

(2016) Tiziana Pernice et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the “Supply Problem”

(2016) Nelson Gomes et al.   Marine Drugs

Drugs and Drug Candidates from Marine Sources: An Assessment of the Current “State of Play”

(2016) David Newman et al.   PLANTA MEDICA

Cyclic depsipeptides as potential cancer therapeutics

(2015) Jirouta Kitagaki et al.   ANTI-CANCER DRUGS

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function

(2015) Antoinette R. Tan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors

(2015) Mark J. Ratain et al.   INVESTIGATIONAL NEW DRUGS

HPLC–MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model

(2015) Laura Ceriani et al.   Bioanalysis

How might we increase success in marine-based drug discovery?

(2014) Andrew P Desbois   Expert Opinion on Drug Discovery

Discontinued in 2013: oncology drugs

(2014) Robert Williams   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Anticancer agents from marine sponges

(2014) Jianjun Ye et al.   JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH

Quantification of trabectedin in human plasma: Validation of a high-performance liquid chromatography–mass spectrometry method and its application in a clinical pharmacokinetic study

(2014) Monique Zangarini et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Stellatolides, a New Cyclodepsipeptide Family from the Sponge Ecionemia acervus: Isolation, Solid-Phase Total Synthesis, and Full Structural Assignment of Stellatolide A

(2014) María Jesús Martín et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development

(2014) David Newman et al.   Marine Drugs

Marketed Marine Natural Products in the Pharmaceutical and Cosmeceutical Industries: Tips for Success

(2014) Ana Martins et al.   Marine Drugs

Utility of noninvasive biomatrices in pharmacokinetic studies

(2013) Kanumuri Siva Rama Raju et al.   BIOMEDICAL CHROMATOGRAPHY

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia withJAK2-V617F mutation

(2013) Elizabeth Hexner et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

(2013) J. Capdevila et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Discontinued drugs in 2012: oncology drugs

(2013) Robert Williams   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

(2013) Ivana Gojo et al.   INVESTIGATIONAL NEW DRUGS

Liquid chromatography–tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis

(2013) Philippe Bourget et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Finding chemo: the search for marine-based pharmaceutical drugs active against cancer

(2013) Sivanjah Indumathy et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

The first total synthesis of the cyclodepsipeptide pipecolidepsin A

(2013) Marta Pelay-Gimeno et al.   Nature Communications

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors

(2012) R. Salazar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lessons from the Past and Charting the Future of Marine Natural Products Drug Discovery and Chemical Biology

(2012) William H. Gerwick et al.   CHEMISTRY & BIOLOGY

Bioactive Peptides and Depsipeptides with Anticancer Potential: Sources from Marine Animals

(2012) Guadalupe-Miroslava Suarez-Jimenez et al.   Marine Drugs

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

(2011) Sylvain Baruchel et al.   EUROPEAN JOURNAL OF CANCER

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Validation of high-performance liquid chromatography–tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices

(2011) A.C. Dubbelman et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure

(2011) Yuri Yamazaki et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

(2011) Teri N. Kreisl et al.   NEURO-ONCOLOGY

Bioanalytical aspects of clinical mass balance studies in oncology

(2011) Anne-Charlotte Dubbelman et al.   Bioanalysis

A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors

(2010) Muhammad Wasif Saif et al.   ANTI-CANCER DRUGS

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs

(2010) Robert S. Jansen et al.   MASS SPECTROMETRY REVIEWS

A review of current trends and advances in modern bio-analytical methods: Chromatography and sample preparation

(2009) Lucie Nováková et al.   ANALYTICA CHIMICA ACTA

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

(2009) Shivaani Kummar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

(2009) T. N. Kreisl et al.   CLINICAL CANCER RESEARCH

Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine

(2009) Hirofumi Nakano et al.   JOURNAL OF ANTIBIOTICS

A novel strategy for reducing phospholipids-based matrix effect in LC–ESI-MS bioanalysis by means of HybridSPE

(2009) Vincenzo Pucci et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

(2009) Patrick Schöffski et al.   Marine Drugs

Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects

(2008) Ricardo Nalda-Molina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

(2008) C. S. Mitsiades et al.   CANCER RESEARCH

A high-performance liquid chromatography–tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma

(2008) C DESJARDINS et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES